Request appointment
1275 York AvenueNew York, NY 10065
Overview of Dr. Modak
Dr. Shakeel Modak is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He received his medical degree from Topiwala National Medical College and has been in practice 38 years. He is one of 110 doctors at Memorial Sloan Kettering Cancer Center and one of 133 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
Central Iowa Health System (Iowa Methodist Medical Center)Residency, Pediatrics, 1995 - 1996
Topiwala National Medical CollegeClass of 1988
Certifications & Licensure
NY State Medical License 2001 - 2027
IA State Medical License 1995 - 1996
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014-2020
Clinical Trials
- Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
Publications & Presentations
PubMed
- 18F-mFBG PET Detects Neuroblastoma Recurrence Prior to 123I-mIBG SPECT.Shakeel Modak, Gerald Behr, Arnold F Jacobson, Neeta Pandit-Taskar
Journal of Pediatric Hematology/oncology. 2026-11-05 - Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma.Salvatore M Aspromonte, Tamar Y Feinberg, Somali Gavane, Candace Parker, Ali Cihan
Journal of Nuclear Medicine. 2026-11-02 - Single Autologous Stem Cell Rescue After Single or TandemI-Metaiodobenzylguanidine Therapy, With or Without Subsequent Chemotherapy, for Resistant Neuroblastoma: Feasi...Wei Wei, Ellen Basu, Brian H Kushner, Madhavi Lakkaraja, Kim Kramer
Pediatric Blood & Cancer. 2026-10-01
Press Mentions
- Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary EndpointMay 26th, 2022
- Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (Naxitamab-Gqgk) Frontline and HITS Data in High-Risk NeuroblastomaSeptember 10th, 2021
Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16December 7th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: